We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Review · October 23, 2020

Future Perspectives and Challenges With CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer

Future Oncology (London, England)


Additional Info

Disclosure statements are available on the authors' profiles:

Future Oncology (London, England)
Future Perspectives and Challenges With CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer
Future Oncol 2020 Aug 17;[EPub Ahead of Print], S Bayraktar, S Batoo, E Al-Hattab, S Basu, S Okuno, S Glück

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading